Literature DB >> 24778013

Neamine inhibits oral cancer progression by suppressing angiogenin-mediated angiogenesis and cancer cell proliferation.

Koji Kishimoto1, Shoko Yoshida, Soichiro Ibaragi, Norie Yoshioka, Guo-Fu Hu, Akira Sasaki.   

Abstract

BACKGROUND: Angiogenin undergoes nuclear translocation and stimulates ribosomal RNA transcription in both endothelial and cancer cells. Consequently, angiogenin has a dual effect on cancer progression by inducing both angiogenesis and cancer cell proliferation. The aim of this study was to assess whether neamine, a blocker of nuclear translocation of angiogenin, possesses antitumor activity toward oral cancer.
MATERIALS AND METHODS: The antitumor effect of neamine on oral cancer cells was examined both in vitro and in vivo.
RESULTS: Neamine inhibited the proliferation of HSC-2, but not that of SAS oral cancer cells in vitro. Treatment with neamine effectively inhibited growth of HSC-2 and SAS cell xenografts in athymic mice. Neamine treatment resulted in a significant decrease in tumor angiogenesis, accompanied by a decrease in angiogenin- and proliferating cell nuclear antigen-positive cancer cells, especially of HSC-2 tumors.
CONCLUSION: Neamine effectively inhibits oral cancer progression through inhibition of tumor angiogenesis. Neamine also directly inhibits proliferation of certain types of oral cancer cells. Therefore, neamine has potential as a lead compound for oral cancer therapy.

Entities:  

Keywords:  Neamine; angiogenesis; angiogenin; cell proliferation; oral cancer

Mesh:

Substances:

Year:  2014        PMID: 24778013      PMCID: PMC4757496     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  28 in total

1.  Wet autoclave pretreatment improves the visualization of silver-stained nucleolar organizer-region-associated proteins in routinely formalin-fixed and paraffin-embedded tissues.

Authors:  D Ofner; A Bankfalvi; K Riehemann; B Bier; W Böcker; K W Schmid
Journal:  Mod Pathol       Date:  1994-12       Impact factor: 7.842

2.  Angiogenin activates Erk1/2 in human umbilical vein endothelial cells.

Authors:  S Liu; D Yu; Z P Xu; J F Riordan; G F Hu
Journal:  Biochem Biophys Res Commun       Date:  2001-09-14       Impact factor: 3.575

3.  Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness.

Authors:  S Shimoyama; F Gansauge; S Gansauge; G Negri; T Oohara; H G Beger
Journal:  Cancer Res       Date:  1996-06-15       Impact factor: 12.701

Review 4.  Angiogenesis in oral cancer.

Authors:  R Hasina; M W Lingen
Journal:  J Dent Educ       Date:  2001-11       Impact factor: 2.264

5.  Neomycin inhibits angiogenin-induced angiogenesis.

Authors:  G F Hu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

6.  The nuclear function of angiogenin in endothelial cells is related to rRNA production.

Authors:  Zheng-ping Xu; Takanori Tsuji; James F Riordan; Guo-fu Hu
Journal:  Biochem Biophys Res Commun       Date:  2002-06-07       Impact factor: 3.575

7.  Identification and characterization of an angiogenin-binding DNA sequence that stimulates luciferase reporter gene expression.

Authors:  Zheng-ping Xu; Takanori Tsuji; James F Riordan; Guo-fu Hu
Journal:  Biochemistry       Date:  2003-01-14       Impact factor: 3.162

8.  A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity.

Authors:  Richard Y T Kao; Jeremy L Jenkins; Karen A Olson; Marc E Key; James W Fett; Robert Shapiro
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-12       Impact factor: 11.205

9.  Angiogenin antagonists prevent tumor growth in vivo.

Authors:  K A Olson; J W Fett; T C French; M E Key; B L Vallee
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-17       Impact factor: 11.205

10.  A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice.

Authors:  K A Olson; T C French; B L Vallee; J W Fett
Journal:  Cancer Res       Date:  1994-09-01       Impact factor: 12.701

View more
  6 in total

1.  Neamine is preferential as an anti-prostate cancer reagent by inhibiting cell proliferation and angiogenesis, with lower toxicity than cis-platinum.

Authors:  Ya-Ping Liu; Guo-Fu Hu; Yun-Xia Wu
Journal:  Oncol Lett       Date:  2015-05-19       Impact factor: 2.967

2.  Angiogenin is upregulated during the alloreactive immune response and has no effect on the T-cell expansion phase, whereas it affects the contraction phase by inhibiting CD4+ T-cell apoptosis.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Maria Sounidaki; Nikolaos Antoniadis; Georgia Antoniadi; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Exp Ther Med       Date:  2016-10-06       Impact factor: 2.447

3.  Angiogenin negatively regulates the expression of basic fibroblast growth factor (bFGF) and inhibits bFGF promoter activity.

Authors:  Jia Zhao; Dezhong Wen; Wenhua Jiang; Jinna Song; Jianli Yang; Xiang Gao; Hui Xue; Li Wang
Journal:  Int J Clin Exp Pathol       Date:  2018-07-01

4.  Neamine inhibits growth of pancreatic cancer cells in vitro and in vivo.

Authors:  Ya-Ping Liu; Yan-Li Wu; Xiao-Yan Zhang; Guo-Fu Hu; Yun-Xia Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-02-03

5.  Angiogenin secretion from hepatoma cells activates hepatic stellate cells to amplify a self-sustained cycle promoting liver cancer.

Authors:  Cristina Bárcena; Milica Stefanovic; Anna Tutusaus; Guillermo A Martinez-Nieto; Laura Martinez; Carmen García-Ruiz; Alvaro de Mingo; Juan Caballeria; José C Fernandez-Checa; Montserrat Marí; Albert Morales
Journal:  Sci Rep       Date:  2015-01-21       Impact factor: 4.379

6.  Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays.

Authors:  Yash Gupta; Dawid Maciorowski; Samantha E Zak; Krysten A Jones; Rahul S Kathayat; Saara-Anne Azizi; Raman Mathur; Catherine M Pearce; David J Ilc; Hamza Husein; Andrew S Herbert; Ajay Bharti; Brijesh Rathi; Ravi Durvasula; Daniel P Becker; Bryan C Dickinson; John M Dye; Prakasha Kempaiah
Journal:  Methods       Date:  2021-01-14       Impact factor: 3.608

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.